MX2022016183A - Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina. - Google Patents

Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.

Info

Publication number
MX2022016183A
MX2022016183A MX2022016183A MX2022016183A MX2022016183A MX 2022016183 A MX2022016183 A MX 2022016183A MX 2022016183 A MX2022016183 A MX 2022016183A MX 2022016183 A MX2022016183 A MX 2022016183A MX 2022016183 A MX2022016183 A MX 2022016183A
Authority
MX
Mexico
Prior art keywords
ylethanamine
pyridin
phenyl
topical formulations
pharmaceutically acceptable
Prior art date
Application number
MX2022016183A
Other languages
English (en)
Inventor
Rajesh Kumar
Robert Berman
Charles M Conway
Mary K Donohue
Ajaya Kumar Reka
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2022016183A publication Critical patent/MX2022016183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporciona una formulación farmacéutica que incluye (1S)-1-fenil-2-piridin-2-iletanamina, una sal aceptable desde el punto de vista farmacéutico de esta, un solvato de esta o un profármaco de esta; y un portador tópico aceptable desde el punto de vista farmacéutico. También se proporciona un método para tratar el dolor neuropático al administrar a un paciente que necesite tal tratamiento una cantidad terapéuticamente eficaz de la formulación farmacéutica.
MX2022016183A 2020-06-23 2021-06-23 Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina. MX2022016183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043075P 2020-06-23 2020-06-23
PCT/US2021/038564 WO2021262779A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Publications (1)

Publication Number Publication Date
MX2022016183A true MX2022016183A (es) 2023-02-13

Family

ID=79281832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016183A MX2022016183A (es) 2020-06-23 2021-06-23 Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.

Country Status (12)

Country Link
US (1) US12564579B2 (es)
EP (1) EP4168116A4 (es)
JP (1) JP2023531918A (es)
KR (1) KR20230026449A (es)
CN (1) CN115836052A (es)
AU (1) AU2021297823A1 (es)
BR (1) BR112022025900A2 (es)
CA (1) CA3187140A1 (es)
IL (1) IL299308A (es)
MX (1) MX2022016183A (es)
PH (1) PH12022553502A1 (es)
WO (1) WO2021262779A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220093A2 (en) * 2023-04-20 2024-10-24 LifeActive, Inc. Transdermal delivery formulations and methods for the manufacture thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2571904B2 (ja) * 1991-07-17 1997-01-16 フアイザー・インコーポレイテツド 抗虚血剤としての２−（４−ヒドロキシピペリジノ）−１−アルカノール誘導体
EP0633879B1 (en) * 1992-04-03 1998-03-11 Astra Aktiebolag Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
PL4001272T3 (pl) 2013-11-05 2025-02-10 Astrazeneca Ab Proleki antagonisty nmda
US11358935B2 (en) * 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases

Also Published As

Publication number Publication date
KR20230026449A (ko) 2023-02-24
IL299308A (en) 2023-02-01
PH12022553502A1 (en) 2024-04-22
US12564579B2 (en) 2026-03-03
WO2021262779A1 (en) 2021-12-30
CN115836052A (zh) 2023-03-21
US20230190719A1 (en) 2023-06-22
BR112022025900A2 (pt) 2023-01-10
EP4168116A4 (en) 2024-07-10
EP4168116A1 (en) 2023-04-26
CA3187140A1 (en) 2021-12-30
AU2021297823A1 (en) 2023-02-16
JP2023531918A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2022003845A (es) Tratamientos cognitivos medicinales.
WO2021022058A3 (en) Antiarrhythmic formulation
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MX2026001173A (es) Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor
PH12022553502A1 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2020170032A3 (en) Method for treatment of rosacea in patients aged 65 years and older
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
MX2023010394A (es) Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd.
MX2025001642A (es) Tratamiento del cancer de piel
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
PH12021553098A1 (en) Treatment for synucleinopathies
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
IL319025A (en) Methods for treating or preventing endometriosis
ZA202400915B (en) Pharmaceutical composition and use thereof
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
MX2023009424A (es) Composicion antitranspirante.
MX2018013477A (es) Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.